# Relmada Therapeutics, Inc.: Form 8-K, filed Sep 20, 2023

- Company: [Relmada Therapeutics, Inc.](/companies/rlmd.md) (CIK 1553643)
- Form: 8-K
- Filed: 2023-09-20
- Accepted by EDGAR: Sep 20, 2023, 16:47 ET
- Period: 2023-09-20
- Accession: 0001213900-23-078049
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023078049/ea185487-8k_relmada.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1553643/000121390023078049/

## Items reported

- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1553643/000121390023078049/ea185487-8k_relmada.htm

Filed Sep 20, 2023.
Source: SEC EDGAR, the filing index for accession 0001213900-23-078049. Last ingested by Listed: Nov 13, 2026, 15:42 ET. No prices; not investment advice.
